MYC and prostate cancer: Our group has previously found that PTEN deletions can be sensitively detected using a simple immunohistochemistry (IHC) assay and are significantly associated with adverse oncologic outcomes in surgically treated primary prostate cancer, including up-grading and up-staging at prostatectomy, biochemical recurrence, and metastasis.10, 11, 12, 13 Other work has found that copy number alterations at 8q24, including MYC gene gain, may be associated with Grade Group upgrade at prostatectomy.14